Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Y-MABS THERAPEUTICS INC (YMAB) Stock Price & Overview
NASDAQ:YMAB • US9842411095
Current stock price
8.61 USD
+0.02 (+0.23%)
At close:
8.61 USD
0 (0%)
After Hours:
The current stock price of YMAB is 8.61 USD. Today YMAB is up by 0.23%. In the past month the price increased by 1.06%. In the past year, price decreased by -37.29%.
YMAB Key Statistics
52-Week Range3.55 - 16.11
Current YMAB stock price positioned within its 52-week range.
1-Month Range8.5113 - 8.61
Current YMAB stock price positioned within its 1-month range.
- Market Cap
- 391.238M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.50
- Dividend Yield
- N/A
YMAB Stock Performance
Today
+0.23%
1 Week
+0.29%
1 Month
+1.06%
3 Months
+95.24%
Longer-term
6 Months +72.20%
1 Year -37.29%
2 Years +57.98%
3 Years -40.29%
5 Years -77.57%
10 Years N/A
YMAB Stock Chart
YMAB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to YMAB. When comparing the yearly performance of all stocks, YMAB is one of the better performing stocks in the market, outperforming 85.61% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
YMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to YMAB. While YMAB has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
YMAB Earnings
On August 8, 2025 YMAB reported an EPS of -0.07 and a revenue of 19.52M. The company beat EPS expectations (74.16% surprise) and beat revenue expectations (4.07% surprise).
Next Earnings DateNov 6, 2025
Last Earnings DateAug 8, 2025
PeriodQ2 / 2025
EPS Reported-$0.07
Revenue Reported19.525M
EPS Surprise 74.16%
Revenue Surprise 4.07%
YMAB Forecast & Estimates
16 analysts have analysed YMAB and the average price target is 8.2 USD. This implies a price decrease of -4.75% is expected in the next year compared to the current price of 8.61.
For the next year, analysts expect an EPS growth of -24.97% and a revenue growth -5.98% for YMAB
Analysts
Analysts53.75
Price Target8.2 (-4.76%)
EPS Next Y-24.97%
Revenue Next Year-5.98%
YMAB Index Membership
YMAB is currently included in the following stock indexes tracked on ChartMill.
YMAB Financial Highlights
Over the last trailing twelve months YMAB reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 10.71% compared to the year before.
Income Statements
Revenue(TTM)85.39M
Net Income(TTM)-22.22M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.96% | ||
| ROE | -25.4% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%66.67%
Sales Q2Q%-14.36%
EPS 1Y (TTM)10.71%
Revenue 1Y (TTM)-1.34%
YMAB Ownership
Ownership
Inst Owners82.83%
Shares45.44M
Float39.89M
Ins Owners0.34%
Short Float %N/A
Short RatioN/A
YMAB Industry Overview
YMAB operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 23.0
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.2
YMAB Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.57 | 373.774B | ||
| AMGN | AMGEN INC | 13.82 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.92 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.83 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.74 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.76 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.43 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.042B | ||
| INCY | INCYTE CORP | 10.54 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About YMAB
Company Profile
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Company Info
IPO: 2018-09-21
Y-MABS THERAPEUTICS INC
202 Carnegie Center, Suite 301
Princeton NEW JERSEY 10169 US
CEO: Claus Juan Moller San Pedro
Employees: 104
Phone: 16468858505
Y-MABS THERAPEUTICS INC / YMAB FAQ
What does YMAB do?
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
What is the stock price of Y-MABS THERAPEUTICS INC today?
The current stock price of YMAB is 8.61 USD. The price increased by 0.23% in the last trading session.
Does YMAB stock pay dividends?
YMAB does not pay a dividend.
What is the ChartMill rating of Y-MABS THERAPEUTICS INC stock?
YMAB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about Y-MABS THERAPEUTICS INC (YMAB) stock?
16 analysts have analysed YMAB and the average price target is 8.2 USD. This implies a price decrease of -4.75% is expected in the next year compared to the current price of 8.61.
What is the market capitalization of YMAB stock?
Y-MABS THERAPEUTICS INC (YMAB) has a market capitalization of 391.24M USD. This makes YMAB a Small Cap stock.